

Index

β -catenin, 202–207, 217–222
TP53 tp, 247

A

Aurora Kinase, 352, 355

B

Biomarkers, 120, 121, 124, 132, 137, 142,
146–148, 327–329, 334

C

c-Met, 104, 353, 354
Cancer stem cell (CSC), 179, 188, 189,
191, 206
Cetuximab, 67–78
Chemoresistance, 237
Cisplatin, 56, 63, 68–70, 72, 73, 260, 262, 265,
266, 269–273, 275

D

Detection, 241, 244
Disruptive mutation, 242
DNA methylation, 329, 331
DNA repair, 259, 260, 262, 265, 268, 271,
275, 276
Dose de-escalation, 8, 17, 18

E

Epidermal Growth Factor Receptor (EGFR),
78, 92, 98–102, 349–353
Epigenetics, 205, 326
Epithelial-mesenchymal transition (EMT), 179,
180, 182–192
ErbB family, 56, 58, 63, 71, 72
Erlotinib, 72, 75, 77, 78

F

Fluoroazomycin-arabofuranoside
(FAZA), 290

Fluoromisonidazole, 289

G

Gene expression, 325–332, 334, 335
Genomics, 317, 318

H

Head and neck cancer (HNC), 92, 93, 100,
166–168, 170–172, 179, 181–185,
188–191, 219, 220, 228, 230, 234,
242–246, 308, 315, 325, 332, 343, 344,
347–354
Head and neck squamous cell carcinoma
(HNSCC), 92, 132, 133, 137, 140–143,
145–149, 283–291, 293, 294, 296, 297
Hepatocyte growth factor (HGF), 93, 96–102,
104
Hepatocyte growth factor receptor (HGFR), 92,
93, 95
Human papilloma virus (HPV), 8, 11–15, 18,
23–27, 29, 141–143, 206, 207, 215, 216,
219, 222, 229, 230, 233, 241, 284, 297,
326, 327, 332
markers of, 220
Hypoxia, 284, 285, 287, 289–292,
294–298, 348
Hypoxia induced factor (HIF-1 α), 294, 295

I

Incidence, 30, 32, 34, 36, 38
Insulin receptor substrate (IRS), 115
Insulin receptor substrate-1 (IRS-1), 116,
118, 122
Insulin receptor substrate-2 (IRS-2), 115
Insulin-like growth factor receptor-1 receptor
(IGF1R), 118, 119
Invadopodia, 120

J

Jak, 164, 166, 168, 172

M

Mammalian target of rapamycin (mTOR), 136, 137, 141–143, 145–148
 Metastasis, 117, 119, 120, 122, 179–185, 188–191
 Microarray expression studies, 219
 MicroRNAs (miRs), 179, 189, 326, 332
 Monoclonal antibodies, 58, 67, 71, 73
 Mortality, 31

N

Nitroimidazole, 284, 289, 290, 293
 Notch, 305, 310–315

O

Oncogenome, 208
 Oral cancer, 206
 Oropharyngeal cancer, 13, 29, 34, 36–39, 42
 Oxygen enhancement ratio (OER), 286

P

Phosphatase and tensin homologue (PTEN), 134, 137, 140, 141, 146
 Phosphoinositide 3-kinase (PI3K), 132, 133
 Pimonidazole, 287, 289, 296
 Prognosis, 229, 230, 232, 235, 240, 242

R

Radiation, 56, 66, 68, 69, 73, 260, 262, 265, 266, 270, 272, 273, 275, 276, 284, 286, 287, 291–293, 297
 Radioresistance, 287, 290, 292, 294, 295, 298

Receptor tyrosine kinases (RTKs), 92

S

Sequencing, 304–308, 310, 311, 313, 318
 Signal transduction, 205
 Smad, 180, 181, 183–185
 Snail, 179, 182, 184–187, 189, 191, 192
 Sonic hedgehog (Shh), 218, 353
 Squamous, 306, 310–312, 316
 Squamous cell cancer, 97
 Squamous cell carcinoma, 167
 Squamous cell carcinoma of the head and neck (HNSCC), 200
 Squamous cell carcinoma of the head and neck (SCCHN), 7, 9–11, 13–15, 18, 56–58, 61–63, 65–73, 75, 76
 STAT, 164, 166–170

T

Targeted therapy, 99–101, 105, 173
 Tirapazamine (TPZ), 293, 297
 Transforming growth factor-beta (TGF β), 179–181, 183–185, 187–189, 191
 Tumor suppressor gene, 241
 Twist, 179, 186–189, 191
 Tyrosine kinase inhibitor (TKI), 71, 72

V

Variants, 23, 39–42

W

Wnt wnt, 208
 Wnt pathway, 215–222
 negative regulation of, 223